At UHN, we strive to deliver Compassionate Care & Caring. Learn more about the services and supports that are available to you throughout your journey.
Our UHN programs and services are among the most advanced in the world. We have grouped our physicians,
staff, services and resources into 10 medical programs to meet the needs of our patients and help us make
the most of our resources.
At the heart of everything we do at UHN are our Healthcare Professionals. Refer a patient to one of our 12 medical programs. Learn more about the resources and opportunities available for professional growth.
University Health Network has grown to be one of the largest research and teaching hospital networks in Canada - pioneers in improving the lives of patients. Our long history of health professions education at Toronto General, Toronto Western, Princess Margaret and Toronto Rehab hospitals has consistently advanced the science of education.
University Health Network is a health care and medical research organization in
Toronto, Ontario, Canada. The scope of research and complexity of cases at UHN has made us a national and international
source for discovery, education and patient care.
Being touched by illness affects us in different ways. Many people want to give back to the community
and help others. At UHN, we welcome your contribution and offer different ways you can help so you can find one that suits you.
The Newsroom is the source for media looking for information about UHN or trying to connect with one
of our experts for an interview. It's also the place to find UHN media policies and catch up on our news stories, videos, media releases,
podcasts and more.
For an unknown number of people, their heart disease is caused by a condition called ATTR amyloidosis.
For this widely under-diagnosed, progressive and often fatal disease, there are few options for treatment.
When the protein transthyretin (TTR) falls apart, it can clump together and morph into amyloids – a cluster of misfolded proteins that stick together. These are acutely dangerous when deposits form in the heart, as they can result in amyloid-TTR amyloidosis (ATTR amyloidosis): a type of heart failure long hidden in the shadows, poorly studied.
Princess Margaret Cancer Centre Senior Scientist Avi Chakrabartty says the problem of ATTR amyloidosis being under-recognized is compounded by the fact that standard heart medications – including blood thinners, statins and digoxin – may not work, and may in fact be harmful.
"There seems to be an unmet need for diagnosis and treatment," Dr. Chakrabartty says. "That was the impetus for starting the research."
His lab discovered an antibody target that is hidden when a protein acts normally, but exposed when it falls apart. Less than a decade later, this set the stage for a novel clinical trial that began in late March.
The trial is not accruing patients at this time.